文献速递自身炎症与 IgG4 相关病

托珠单抗治疗成人起病Still病的疗效与安全性:来自国际AIDA登记处的真实世界经验

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.
PubMed 文献 · Semin Arthritis Rheum · 2022-08-30

本研究基于国际AIDA登记处数据,分析31例对传统治疗无效的成人起病Still病(AOSD)患者使用托珠单抗(TCZ)的疗效与安全性。结果显示TCZ可显著降低Pouchot评分和血清炎症指标,12、24、36个月药物留存率分别为83.1%、71.7%和63.7%,并显著减少糖皮质激素日剂量。

要点

  • TCZ治疗31例难治性AOSD患者,Pouchot评分从基线2.00(4.00)降至末次随访0.00(0.00),p=0.032。
  • TCZ在12、24、36个月累积留存率分别为83.1%、71.7%和63.7%,生物制剂初治与经治患者间无显著差异(p=0.329)。
  • 糖皮质激素日剂量从基线18.36±24.72 mg显著降至末次随访4.02±4.99 mg(p=0.003)。

核心结论

  • TCZ可控制AOSD疾病活动度并使血清炎症指标正常化,对全身型和慢性关节型均有效。
  • TCZ显示出极好的药物留存率,同时最小化长期暴露于糖皮质激素的风险。

研究设计与样本

  • 国际多中心研究,分析国际AIDA登记处定期入组的AOSD患者数据。
  • 共纳入31例(15男,16女)对传统治疗无效并接受TCZ治疗的患者。
  • TCZ平均±标准差治疗持续时间为24.32±20.57个月。
  • 疗效通过基线至末次随访评估Pouchot评分和实验室指标变化;药物留存率用Kaplan-Meier法估计,Cox回归分析检测治疗撤药的潜在预测因素。

主要发现

  • 中位(四分位距)Pouchot评分在整个研究期间显著下降(p=0.001),基线[2.00(4.00)]与6个月随访[0.00(0.00)]间(p=0.003)及基线[2.00(4.00)]与末次随访[0.00(0.00)]间(p=0.032)均有显著差异,6个月评估与末次随访间无差异(p=0.823)。
  • 实验室参数从基线至末次随访显著下降。
  • 12、24、36个月随访时TCZ累积留存率分别为83.1%、71.7%和63.7%,生物制剂初治患者与既往使用其他生物制剂患者间无显著差异(p=0.329)。
  • 慢性关节型AOSD与其他疾病病程类型间无显著差异(p=0.938),联合传统免疫抑制剂患者与TCZ单药治疗患者间无显著差异(p=0.778)。
  • Cox回归分析未识别出与治疗撤药风险增高相关的变量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. METHODS: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Meier method, while Cox-regression analysis was employed to detect potential predictive factors of treatment withdrawal. RESULTS: Data from 31 patients (15 men, 16 women) refractory to the conventional therapies and treated with TCZ were extracted from the AIDA registry. Mean ± SD time of treatment duration with TCZ was 24.32 ± 20.57 months. Median (IRQ) Pouchot score significantly decreased throughout the study period (p=0.001) with a significant difference between baseline [2.00 (4.00)] and 6 month-follow-up [0.00 (0.00)] (p=0.003) and between baseline and last follow-up assessment [0.00 (0.00)] (p=0.032), while no differences were observed between 6 month-evaluation and last follow-up assessment (p=0.823). Similarly, laboratory parameters significantly decreased from baseline to the last follow-up visit. With regard to drug survival, cumulative TCZ retention rate at 12-, 24-, and 36-month follow-up visit were 83.1%, 71.7% and 63.7%, respectively, without significant differences between biologic naïve patients and those previously treated with other biologics (p=0.329). Likewise, no significant differences were observed between chronic articular course of AOSD and other types of disease course (p=0.938) or between patients co-administered with conventional immunosuppressants and patients receiving TCZ as monotherapy (p=0.778). Cox-regression analysis identified no variable associated with a higher hazard of treatment withdrawal. Treatment was discontinued in 9 patients due to long-term remission (n=4), adverse events (n=2), loss of efficacy (n=1), non-medical reason (n=1) and unspecified cause (n=1). Mean glucocorticosteroids daily dose significantly decreased from baseline (18.36 ± 24.72 mg) to the last follow-up assessment (4.02 ± 4.99 mg, p=0.003). CONCLUSIONS: TCZ allows control of disease activity as well as normalization of serum inflammatory markers in both systemic and chronic articular form of AOSD. Additionally, TCZ displays an excellent drug retention rate while minimizing the risk of long-term exposure to corticosteroids.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Sota J, Vitale A, Lopalco G, et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry. Semin Arthritis Rheum. 2022. PMID: 36063578. doi:10.1016/j.semarthrit.2022.152089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。